| Name | Title | Contact Details |
|---|
Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.
Homepage for InnerScope Hearing Technologies, a hearing care company who sells Direct-to-Consumer Hearing Aids.
Illyria Consulting Group is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Founded by physician-scientist, Michael E. Mendelsohn, M.D., and built by a team of physician-scientists and industry leaders with extensive experience in cardiovascular disease, drug development and business development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs to target major unmet needs in cardiovascular medicine. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan.